PR97619

EAST RUTHERFORD, NJ , Sept. 1, 2022, /PRNewswire=KYODO JBN/--

Cambrex today announced the completion of the first phase of its $30 million

investment in its small molecule active pharmaceutical ingredient (API)

manufacturing facility in High Point, North Carolina. The newly constructed

space adds analytical and chemical development laboratories totaling 30,000

square feet and provides future workspace for 85 analytical and chemical

development scientists.  These laboratories will support the development of

APIs to be manufactured in the facility's current clinical manufacturing area,

as well as the future expanded clinical manufacturing and commercial

manufacturing suites.

"With the growing number of therapies in clinical development and trend toward

more targeted therapeutics, including orphan drugs, this expansion is preparing

Cambrex to support the growing demand for small-scale API manufacturing," said

Tom Loewald, CEO, Cambrex. "Our expansion goes beyond providing capacity – it

provides state-of-the-art technology and laboratory equipment, an energy

efficient infrastructure, and an ideal space for our scientific experts to work

side-by-side with our clients."

Phase 2 of the project is ongoing and will approximately double the facility's

manufacturing capacity with the addition of clinical and commercial

manufacturing suites with reactors up to 2,000 liters.  The new commercial area

will provide an ideal scale for the manufacturing of orphan drugs and niche

therapies, while larger volume products developed at the facility can be

manufactured commercially at one of Cambrex's larger scale facilities in Iowa

and Sweden. This expansion follows Cambrex's 2021 investment in the Cambrex

High Point continuous flow R&D center of excellence, including expanded

capabilities for continuous flow process development, manufacturing, and scale

up.

Cambrex continues to expand its capabilities and capacity across its North

American and European network to meet the growing demand for outsourced product

development and manufacturing services.

About Cambrex

Cambrex is a leading global contract development and manufacturing organization

(CDMO) that provides drug substance, drug product, and analytical services

across the entire drug lifecycle. With over 40 years of experience and a

growing team of over 2,300 experts servicing global clients from North America

and Europe, Cambrex is a trusted partner in branded and generic markets for API

and finished dosage form development and manufacturing.

Cambrex offers a range of specialized drug substance technologies and

capabilities, including biocatalysis, continuous flow, controlled substances,

solid-state science, material characterization, stability storage, and highly

potent APIs. In addition, Cambrex can support conventional dosage forms,

including oral solids, semi-solids, and liquids, and has the expertise to

manufacture specialty dosage forms such as modified-release, fixed-dose

combination, pediatric, bi-layer tablets, stick packs, topicals, controlled

substances, sterile, and non-sterile ointments.

Contact:  

Jennifer Therrien

Jennifer.therrien@cambrex.com

Photo - https://mma.prnewswire.com/media/1889203/Cambrex_1.jpg

Photo - https://mma.prnewswire.com/media/1889204/Cambrex_2.jpg

Logo - https://mma.prnewswire.com/media/1198585/Cambrex_Logo.jpg

SOURCE: Cambrex